Abiomed Inc. kicked off the trading day on 10/10/19 with a price increase of 1.90%, equivalent to $3.03 relative change for the day. Taking a more long-term approach, ABMD had a 52-week range of $157.47 to $427.70. At the time of this article’s publishing, this stock is trading at $162.34 after starting the trading session at $159.12. At the time of writing, this stock’s 50-day Moving Average stands at $186.44, while the 200-day Moving Average of this stock is currently $267.03.
Currently, this company’s share volume is sitting at $1089305, but has maintained average daily volume of $610.68K. This stock has generated an average Year to Date volume of $633875, alongside an average 20-day volume of $638190. This publicly-traded company’s shares outstanding now amounts to $44.78 million, simultaneously with a float of $44.46 million. The organization now has a market capitalization sitting at $7.27 billion.
Abiomed Inc.(ABMD) Ownership Data
Now let’s turn our focus to how large-scale investors are behaving with this stock. Abiomed Inc.’s current insider ownership accounts for 1.70%, in contrast to 94.70% institutional ownership. According to the most recent latest insider trade that took place on Aug 05 this organization’s Chief Operating Officer exercised an option 4,175 at the rate of 21.55, making the entire transaction hit 89,971 in total value, affecting insider ownership by 132,913. Preceding that transaction, on Aug 05 Company’s Chief Operating Officer sold 8,095 at a price of 206.26, making the whole transaction’s value amount to 1,669,693. This particular insider is now the holder of 124,818 in total.
If we take a glance at the Ownership summary of Abiomed Inc.’s stock, Institutional holders make up 94.70% of its total stock ownership. All together, they are the legal holders of 44.78M shares. If we focus on the top 3 stockholders for this publicly-traded organization, The Vanguard Group, Inc. owns 4,604,733 shares, with PRIMECAP Management Co. in 2nd place owning 3,131,040 shares and Renaissance Technologies LLC in third place with total ownership of 2,431,723 shares.
Abiomed Inc. (ABMD) Earnings and Revenue Data
In the latest quarterly report that this company released, which was put into the public domain on 6/29/2019, the organization reported $1.93 earnings per share (EPS) for the three-month period, surpassing the consensus estimate (set at $0.97) by $0.96.
This company achieved a net margin of 32.35 while generating a return on equity of 29.93. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.12 per share during the current fiscal year.
Abiomed Inc.’s EPS increase for this current 12-month fiscal period is 92.60%, and is forecasted to reach 5.23 in the upcoming year. Looking at the long run, market analysts have predicted that Company’s EPS will increase by 24.20% through the next 5 years, which can be compared against the 99.70% growth it accomplished over the previous five years trading on the market.
Additional Trading Performance Indicators
Now turning our attention to the current performance indicators for Abiomed Inc., this organization’s Quick Ratio in the last reported quarter now stands at 5.90. The company has managed to achieve an average true range (ATR) of 6.50. Alongside those, its PE Ratio stands at $29.04, and its Beta score is 0.38.
Another valuable indicator worth considering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 9.12 for this organization. Similarly, its price to free cash flow for trailing twelve months is now 31.73. Plus, this company’s price to book ratio for the last three-month fiscal period reported is 7.32, whereas its price to cash per share for the last quarter landed at 10.87.
In the same vein, ABMD’s Diluted EPS (Earnings per Share) trailing twelve months was posted at 5.59, a figure that is expected to reach 0.93 in the next reported quarter, and analysts expect it will be 5.23 at the market close of one year from today’s date.